Prostaglandin E2 stimulates motilin release via a cholinergic muscarinic pathway in the dog.
Prostaglandins are well known to be widely distributed in mammalian gastrointestinal tissues and to play a role in the regulation of gastrointestinal hormones and contractions. The present study was undertaken to determine whether prostaglandins have an effect on the endogenous release of motilin in the dog. In six conscious dogs, gastrointestinal contractions were monitored by means of chronically implanted force transducers. Prostaglandin E2 (PGE2; 3, 10, 30 microgram kg-1) was given intravenously during the interdigestive phase I period with or without a muscarinic or nicotinic receptor antagonist. Blood samples were collected from 10 min before, to 30 min after, prostaglandin injection. Indomethacin (5 mg kg-1) was given intravenously to investigate the effect of endogenous prostaglandins on motilin release. PGE2 significantly stimulated motilin release but not gastric contractions. Atropine, but not hexamethonium, blocked PGE2-induced motilin release. Motilin release in response to PGE2 was significantly increased by pretreatment with hexamethonium. Indomethacin inhibited the cyclic release of motilin and gastric phase III contractions. We conclude that PGE2 appears to stimulate motilin release via cholinergic muscarinic pathways, and nicotinic receptors modulate this reaction. PGE2 may be involved in part in the regulation of the cyclic release of motilin and the occurrence of gastric phase III.
Mochiki
E
E
First Department of Surgery, Faculty of Medicine, Gunma University, Maebashi, Japan. emochiki@showa.gunma-u.ac.jp
Nakabayashi
T
T
Suzuki
H
H
Haga
N
N
Asao
T
T
Kuwano
H
H
Itoh
Z
Z
D000818:Animals; D001285:Atropine / Q000494:pharmacology; D002799:Cholinergic Fibers / Q000187:drug effects / Q000378:metabolism*; D003243:Consciousness; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D015232:Dinoprostone / Q000494:pharmacology*; D004285:Dogs; D005215:Fasting / Q000502:physiology; D005260:Female; D005769:Gastrointestinal Motility / Q000187:drug effects* / Q000502:physiology; D018738:Hexamethonium / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D007275:Injections, Intravenous; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000187:drug effects / Q000294:innervation; D008297:Male; D009037:Motilin / Q000097:blood*; D018727:Muscarinic Antagonists / Q000494:pharmacology; D018733:Nicotinic Antagonists / Q000494:pharmacology; D010120:Oxytocics / Q000494:pharmacology*; D011976:Receptors, Muscarinic / Q000378:metabolism*
D016861:Cyclooxygenase Inhibitors; D018727:Muscarinic Antagonists; D018733:Nicotinic Antagonists; D010120:Oxytocics; D011976:Receptors, Muscarinic; D018738:Hexamethonium; D009037:Motilin; D001285:Atropine; D015232:Dinoprostone; D007213:Indomethacin